Poltorak V V, Gladkikh A I, Blokh K O, Brindak O I, Berestovskaia E V, Tur M I
Farmakol Toksikol. 1991 Jan-Feb;54(1):34-7.
The study was carried out on 25 mice of the mutant C57BL/KsJY line carrying the autosomal-recessive gene db (diabetes) in the homozygous state with basal normo- and hyperglycemia by the beginning of the treatment with glybenclamide (the latent and manifest stages of insulin-independent diabetes mellitus). It was found that long-term oral administration of the drug in the therapeutic dose (20 micrograms per mice a day for 3-3.5 months) enhanced the genetically determined disturbances of glucose homeostasis and the insulin-producing apparatus of the pancreas irrespective of the stage of spontaneous diabetes genesis. The development of the organ-specific autoimmune reactions directed to antigens of the pancreatic islands was found.